Travere Therapeutics' Other Operating Expenses fell 2.52% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 86.21%. This contributed to the annual value of $72.9 million for FY2024, which is 537.11% up from last year.
According to the latest figures from Q3 2025, Travere Therapeutics' Other Operating Expenses is $1.6 million, which was up 4.21% from $1.5 million recorded in Q2 2025.
In the past 5 years, Travere Therapeutics' Other Operating Expenses registered a high of $66.7 million during Q1 2024, and its lowest value of -$25.0 million during Q4 2021.
Its 3-year average for Other Operating Expenses is $8.4 million, with a median of $2.1 million in 2024.
Its Other Operating Expenses has fluctuated over the past 5 years, first surged by 1,953.62% in 2021, then slumped by 274.05% in 2022.
Quarterly analysis of 5 years shows Travere Therapeutics' Other Operating Expenses stood at -$25.0 million in 2021, then soared by 103.47% to $868,000 in 2022, then soared by 425.81% to $4.6 million in 2023, then tumbled by 44.06% to $2.6 million in 2024, then decreased by 2.52% to $1.6 million in 2025.
Its Other Operating Expenses stands at $1.6 million for Q3 2025, versus $1.5 million for Q2 2025 and $4.7 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value